EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Administration of a Next‐Generation Probiotic Escherichia coli Nissle 1917‐GLP‐1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes

Jie Luo iD, Yilin Fang, Zhanghua Qi iD, Fengyang Cui iD, Hong Hu, Shengjie Li iD, Tingtao Chen iD, Hongyan Zhang iD

Canadian Journal of Infectious Diseases and Medical Microbiology · 2025-01 · 2025 (1)

DOI: 10.1155/cjid/6675676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Infectious Diseases and Medical Microbiology, online erschienen am 29.01.2025. Verfasst von Jie Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Disease Prevention and Public Health, School of Public Health, Jiangxi Medical College, Nanchang University, Nan…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Natural Science Foundation of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus (DM) is a persistent and steadily progressing metabolic condition distinguished by unregulated high levels of blood glucose. GLP1 receptor agonists have recently gained recognition as first‐line therapies in selected instances, as per the updated ADA guidelines, highlighting their efficacy not only in glycemic control but also in their broader health benefits. Nonetheless, the efficacy of GLP‐1 is limited by its brief duration of action, rapid clearance from the body, and challenges associated with subcutaneous administration. In this study, we examined the potential diabetes‐mitigating effects of a genetically engineered strain of Escherichia coli Nissle 1917 (EcN)‐GLP‐1, previously developed by our group. We utilized mouse models for both Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) to assess its efficacy. In the case of T1DM mice, the results revealed that EcN‐GLP‐1 resulted in a notable decrease in blood glucose levels. Furthermore, it exhibited a protective influence on the structural integrity of islet β ‐cells; downregulated the expressions of key inflammatory markers such as TLR‐4, p‐NF‐ κ B/NF‐ κ B, and Bax/Bcl‐2; promoted the insulin secretion; and reinstated the perturbed diversity of microbial species to a normal state. Similarly, EcN‐GLP‐1 had a pronounced impact on T2DM mice, manifesting increased presence of islet β ‐cells, decreased inflammatory response and apoptosis, and regulation of lipid metabolism in the liver. In summary, the genetically modified EcN‐GLP‐1 strain demonstrates the ability to alleviate diabetes by enhancing the islet β ‐cell population, mitigating inflammatory reactions and apoptosis, optimizing liver lipid metabolism, and reinstating a balanced microbial diversity. These findings hold promise as a potential avenue for treating DM.

Schlagwörter

Stichwörter der Autor:innen

EcN-GLP-1diabetes mellitusinflammationintestinal microbiotaislet β-cell

Autor:innen und Institutionen

  • Jiangxi Provincial Key Laboratory of Disease Prevention and Public Health, School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Jiangxi Province Key Laboratory of Bioengineering Drugs, School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.
  • Medical Center of Burn Plastic and Wound Repair, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

ORCID-Profile: Jie Luo, Zhanghua Qi, Fengyang Cui, Shengjie Li, Tingtao Chen, Hongyan Zhang

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Natural Science Foundation of Jiangxi Province

Zitieren

APA

Luo, J., Fang, Y., Qi, Z., Cui, F., Hu, H., Li, S., Chen, T., & Zhang, H. (2025). Administration of a Next‐Generation Probiotic Escherichia coli Nissle 1917‐GLP‐1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes. Canadian Journal of Infectious Diseases and Medical Microbiology, 2025(1). https://doi.org/10.1155/cjid/6675676

Vancouver

Luo J, Fang Y, Qi Z, Cui F, Hu H, Li S, et al. Administration of a Next‐Generation Probiotic Escherichia coli Nissle 1917‐GLP‐1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes. Canadian Journal of Infectious Diseases and Medical Microbiology. 2025;2025(1). doi:10.1155/cjid/6675676

BibTeX
@article{Luo2025,
  author = {Luo, Jie and Fang, Yilin and Qi, Zhanghua and Cui, Fengyang and Hu, Hong and Li, Shengjie and Chen, Tingtao and Zhang, Hongyan},
  title = {Administration of a Next‐Generation Probiotic Escherichia coli Nissle 1917‐GLP‐1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes},
  journal = {Canadian Journal of Infectious Diseases and Medical Microbiology},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/cjid/6675676}
}
Kostenlos starten →